Further Upside For Aelis Farma SA (EPA:AELIS) Shares Could Introduce Price Risks After 68% Bounce
Jan 27
Have your own idea? Try our Stock Screener
French (CAC) Biotech Industry Analysis
UpdatedFeb 01, 2025
DataAggregated Company Financials
Companies26
- 7D4.2%
- 3M-14.6%
- 1Y-25.2%
- YTD-1.1%
The Biotech industry is up 2.5% in the last week, with Valneva up 20%. During this same period, the DBV Technologies underperformed, falling 8.3%. In contrast, the industry has lost 29% in the last 12 months. Looking forward, earnings are forecast to grow by 12% annually.
Industry Valuation and Performance
Has the French Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 01 Feb 2025 | €2.4b | €650.1m | -€526,632,992.52 | 16.7x | -4.6x | 3.7x |
| Mon, 30 Dec 2024 | €2.3b | €650.1m | -€526,531,701.82 | 17.4x | -4.4x | 3.6x |
| Wed, 27 Nov 2024 | €2.4b | €654.3m | -€548,494,249.98 | 17.7x | -4.4x | 3.7x |
| Fri, 25 Oct 2024 | €2.8b | €627.7m | -€519,179,326.17 | 18.6x | -5.4x | 4.4x |
| Sun, 22 Sep 2024 | €2.9b | €543.7m | -€590,214,401.80 | 22.5x | -5x | 5.4x |
| Tue, 20 Aug 2024 | €3.1b | €520.3m | -€579,709,875.05 | 37.2x | -5.4x | 6x |
| Thu, 18 Jul 2024 | €3.0b | €511.6m | -€565,692,574.58 | 29.8x | -5.3x | 5.9x |
| Sat, 15 Jun 2024 | €3.0b | €514.4m | -€569,576,604.39 | 26.4x | -5.2x | 5.8x |
| Mon, 13 May 2024 | €3.2b | €502.5m | -€593,891,697.18 | 27.7x | -5.4x | 6.4x |
| Wed, 10 Apr 2024 | €3.3b | €516.1m | -€623,252,845.77 | 22.4x | -5.2x | 6.3x |
| Fri, 08 Mar 2024 | €3.1b | €558.5m | -€672,379,903.07 | 21.9x | -4.6x | 5.6x |
| Sun, 04 Feb 2024 | €3.1b | €594.7m | -€685,665,134.00 | 22.2x | -4.5x | 5.2x |
| Tue, 02 Jan 2024 | €3.2b | €594.0m | -€681,719,515.00 | 23.4x | -4.7x | 5.4x |
| Thu, 30 Nov 2023 | €3.2b | €594.2m | -€682,787,538.00 | 22.4x | -4.6x | 5.3x |
| Sat, 28 Oct 2023 | €3.2b | €804.1m | -€567,175,295.00 | 21.2x | -5.7x | 4x |
| Mon, 25 Sep 2023 | €3.7b | €866.8m | -€616,090,262.00 | 25.9x | -6x | 4.3x |
| Wed, 23 Aug 2023 | €3.7b | €818.3m | -€726,818,352.00 | 24.4x | -5.1x | 4.5x |
| Fri, 21 Jul 2023 | €3.7b | €817.1m | -€733,197,324.00 | 24.9x | -5.1x | 4.6x |
| Sun, 18 Jun 2023 | €3.9b | €820.3m | -€741,652,850.00 | 25.5x | -5.2x | 4.7x |
| Tue, 16 May 2023 | €3.9b | €831.4m | -€760,619,098.00 | 25.9x | -5.1x | 4.7x |
| Thu, 13 Apr 2023 | €3.5b | €946.0m | -€697,243,069.00 | 18.5x | -5.1x | 3.7x |
| Sat, 11 Mar 2023 | €3.5b | €1.0b | -€468,822,749.00 | 10x | -7.4x | 3.3x |
| Mon, 06 Feb 2023 | €3.8b | €1.0b | -€455,464,632.00 | 12.3x | -8.3x | 3.6x |
| Wed, 04 Jan 2023 | €3.7b | €1.0b | -€457,259,649.00 | 12.6x | -8x | 3.6x |
| Fri, 02 Dec 2022 | €3.5b | €1.0b | -€458,275,559.00 | 12.8x | -7.6x | 3.4x |
| Sun, 30 Oct 2022 | €3.6b | €914.3m | -€703,855,276.00 | 17x | -5.1x | 3.9x |
| Tue, 27 Sep 2022 | €3.5b | €954.4m | -€710,773,215.00 | 31.6x | -4.9x | 3.6x |
| Thu, 25 Aug 2022 | €4.5b | €931.9m | -€752,003,336.00 | 119.5x | -6x | 4.9x |
| Sat, 23 Jul 2022 | €4.4b | €983.8m | -€686,883,827.00 | 121.1x | -6.4x | 4.5x |
| Mon, 20 Jun 2022 | €4.0b | €990.2m | -€693,957,202.00 | 125.6x | -5.8x | 4.1x |
| Wed, 18 May 2022 | €4.5b | €992.6m | -€683,817,385.00 | 139.6x | -6.6x | 4.5x |
| Fri, 15 Apr 2022 | €5.2b | €1.2b | -€487,299,676.00 | 3x | -10.6x | 4.2x |
| Sun, 13 Mar 2022 | €5.1b | €946.0m | -€653,167,578.00 | 16.9x | -7.8x | 5.4x |
| Tue, 08 Feb 2022 | €5.3b | €927.5m | -€675,562,084.00 | 3x | -7.9x | 5.8x |
Price to Earnings Ratio
-7.9x
Current Industry PE
- Investors are pessimistic on the French Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 4.7x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 11% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the French Healthcare industry?
| FR Market | 0.38% | |
| Healthcare | 4.18% | |
| Biotech | 4.24% | |
| Biotech | 4.24% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| VLA Valneva | €2.73 | 20.1% +€74.0m | -23.0% | PS2.8x | |
| ALERS Eurobio Scientific Société anonyme | €26.50 | 4.5% +€11.6m | 50.6% | PE40.1x | |
| OSE OSE Immunotherapeutics | €6.81 | 6.9% +€9.6m | 83.1% | PE3.2x | |
| GNFT Genfit | €3.58 | 4.5% +€7.7m | 0% | PE8x | |
| IPH Innate Pharma | €1.80 | 5.4% +€7.7m | -23.4% | PS4.5x |
